Файл: Key words anticoagulant therapy, advanced age, atrial fibrillation, chronic kidney disease. Введение.docx
ВУЗ: Не указан
Категория: Не указан
Дисциплина: Не указана
Добавлен: 08.11.2023
Просмотров: 21
Скачиваний: 2
ВНИМАНИЕ! Если данный файл нарушает Ваши авторские права, то обязательно сообщите нам.
40. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:6035
41. Zhu W, Wan R, Liu F, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. J Am Heart Assoc 2016;5:e4006. [29]. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071104.
42. Marinigh R, Lane DA, Lip GYH. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57(12):1339‐1348. 10.1016/j.jacc.2010.12.013.
43. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662‐2668. 10.2215/CJN.04550511.
44. Providência R, Marijon E, Boveda S, et al. Meta‐analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114(4):646‐653. 10.1016/j.amjcard.2014.05.048.
45. Bonde AN, Lip GYH, Kamper A‐L, et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study. Stroke. 2016;47(11):2707‐2713. 10.1161/STROKEAHA.116.014422.
46. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893962.
47. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:26372.
48. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093100.
49. Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? JAMA 2014;311:9135.
50. van Gorp RH, Schurgers LJ. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients 2015;7:953857.
51. Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009;54:46877.
52. Banerjee A, Fauchier L, Vourc’h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014;145:137082.
53. Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open 2017;7:e014294.
54. Ng KP, Edwards NC, Lip GY, et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 2013;62:61532.
55. Brancaccio D, Neri L, Bellocchio F, et al. Patients' characteristics affect the survival benefit of warfarin treatment for hemodialysis patients with atrial fibrillation. A historical cohort study. Am J Nephrol. 2016;44(4):258‐267. 10.1159/000448898.
56. Olesen JB, Lip GYH, Kamper A‐L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625‐635. 10.1056/NEJMoa1105594.
57. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129(11):1196‐1203. 10.1161/CIRCULATIONAHA.113.004777.
58. Shen JI, Montez‐Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66(4):677‐688. 10.1053/j.ajkd.2015.05.019.
59. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223‐2233. 10.1681/ASN.2009030319. ]
60. Tan J, Liu S, Segal JB, Alexander GC, McAdams‐DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta‐analysis. BMC Nephrol. 2016;17(1):157 10.1186/s12882-016-0368-6.
61. Lee M, Saver JL, Hong K‐S, et al. Warfarin use and risk of stroke in patients with atrial fibrillation undergoing hemodialysis: a meta‐analysis. Medicine. 2016;95(6):e2741 10.1097/MD.0000000000002741. 30>50>50>30>30>50>30>50>